Annexon (ANNX) vs Inventiva S.A. American Depository Shares (IVA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Annexon (ANNX) has outperformed Inventiva S.A. American Depository Shares (IVA) over the past year, gaining 27.0% versus a loss of 38.1%. Over five years, IVA leads with a -75.2% price change compared with -81.8% for ANNX. Inventiva S.A. American Depository Shares is the larger company by market cap ($784.3 million vs $758.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANNX | IVA |
|---|---|---|
| Share price | $4.00 | $3.32 |
| Market cap | $758.32M | $784.25M |
| 1-day change | -0.25% | -1.34% |
| YTD return | -20.32% | -28.60% |
| 1-year return | +26.98% | -38.06% |
| 5-year return | -81.82% | -75.22% |
| EPS (TTM) | $-1.13 | $-0.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.18 | $7.98 |
| 52-week low | $2.54 | $3.11 |
| Distance from 52-week high | -44.29% | -58.41% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +285.75% | +357.83% |
| Average volume | 3.11M | 1.39M |
| Shares outstanding | 189.58M | 236.22M |
| Employees | 92 | 87 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANNX has outperformed IVA by 65.0 percentage points over the past year.
- The two companies sit in different sectors: Annexon in Healthcare and Inventiva S.A. American Depository Shares in Health Care.
About Annexon
ANNX stock →Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis.
Healthcare · Biotechnology · 92 employees
About Inventiva S.A. American Depository Shares
IVA stock →Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses.
Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees
ANNX vs IVA FAQ
Which is bigger, Annexon or Inventiva S.A. American Depository Shares?
Inventiva S.A. American Depository Shares (IVA) is larger, with a market capitalization of $784.25M compared with $758.32M for Annexon (ANNX).
Which stock has performed better over the past year, ANNX or IVA?
ANNX returned +26.98% over the past 12 months, compared with -38.06% for IVA (price return, excluding dividends). Past performance does not predict future results.
Are Annexon and Inventiva S.A. American Depository Shares in the same industry?
No. Annexon is in the Healthcare sector, while Inventiva S.A. American Depository Shares is in Health Care.